Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAT2A | P31153 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29909089 | 0.97 | KCNH2 (0.41) | KCNH2ACHEKMT2AGAATAAR1 | |
| SCHEMBL5517869 | 0.85 | ALDH1A1 (0.38) | KCNH2ACHEKMT2AGAATAAR1 | |
| SCHEMBL9228264 | 0.85 | ACHE (0.50) | KCNH2ACHEALDH1A1NLRP3TSHR | |
| SCHEMBL9228613 | 0.83 | KCNH2 (0.46) | KCNH2KMT2AGAATAAR1ALDH1A1 | |
| SCHEMBL28773561 | 0.83 | PTGS2 (0.41) | KCNH2ACHEKMT2AGAATAAR1 | |
| SCHEMBL13436019 | 0.83 | KCNH2 (0.36) | KCNH2ACHEKMT2AGAATAAR1 | |
| SCHEMBL28740358 | 0.83 | KCNH2 (0.36) | KCNH2ACHEKMT2AGAATAAR1 | |
| SCHEMBL4929104 | 0.83 | HDAC1 (0.46) | KCNH2ACHEKMT2AGAATAAR1 | |
| SCHEMBL5512079 | 0.83 | PDE4D (0.38) | KCNH2KMT2AGAAALDH1A1CES2 | |
| SCHEMBL5511699 | 0.81 | TSHR (0.38) | KCNH2ACHEKMT2AGAATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110218206-B | Bisindolylmaleimide derivative and preparation method and application thereof | 中国海洋大学 | 2022-03-04 | — | — | CN | claimed |
| CN-110526903-B | Bisindolylmaleimide derivative and preparation method and application thereof | 中国海洋大学 | 2021-12-10 | — | — | CN | claimed |
| CN-119661516-A | Bicyclic heterocyclic compounds, preparation method and medical application thereof | 华润医药研究院（深圳）有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-115181092-B | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| EP-4265599-A1 | PYRIMIDINE CARBOXAMIDE COMPOUND AND USE THEREOF | Shanghai Meiyue Biotech Development Co., Ltd. (CN) | 2023-10-25 | — | — | EP | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230192626-A1 | NOVEL SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHOD OF USE THEREOF | BAYLOR COLLEGE OF MEDICINE (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192626-A1 | NOVEL SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHOD OF USE THEREOF | BAYLOR COLLEGE OF MEDICINE (US) | 2023-06-22 | — | — | US | disclosed |
| EP-3436446-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-06-07 | — | — | EP | disclosed |
| CN-116209658-A | Inhibitors of RHO-associated coiled coil kinase | 安吉昂生物医药公司 | 2023-06-02 | — | — | CN | disclosed |
| WO-2023064584-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY (US) | 2023-04-20 | — | — | WO | disclosed |
| US-20120135981-A1 | NOVEL SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-05-31 | — | — | US | disclosed |
| US-8168663-B2 | Pharmaceutically acceptable salt of 6-carboxy-2-(3,5 dichlorophenyl)-benzoxazole, and a pharmaceutical composition comprising the salt thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-05-01 | — | — | US | disclosed |
| US-20120065237-A1 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-03-15 | — | — | US | disclosed |
| EP-2308858-A1 | Isoxazoline Compounds and their Use in Pest Control | Sumitomo Chemical Company, Limited (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-20100273842-A1 | AMINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY AND THE USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20100267945-A1 | AMINE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20100120919-A1 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-05-13 | — | — | US | disclosed |
| CN-1279031-C | Optically active herbicidal (R)-phenoxypropionic acid-N-methyl-N-2-fluorophenyl amides | DONGBU HANNONG CHEMICAL CO LTD (KR) | 2006-10-11 | — | — | CN | disclosed |
| CN-1558717-A | Optically active (R) -phenoxypropionic acid-N-methyl-N-2-fluorophenylamide compounds having herbicidal activity | ������ũ��ѧ��ʽ���� | 2004-12-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273842-A1 | AMINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY AND THE USES THEREOF | NPY5R, NPY1R, NPY2R | KCNH2 801/4885ACHE 2624/4885KMT2A 2321/4885 |
| US-20230192626-A1 | NOVEL SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHOD OF USE THEREOF | EPHX1, EPHX2, NCEH1 | KCNH2 4351/4885ACHE 100/4885KMT2A 3008/4885 |
| US-20100267945-A1 | AMINE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | KCNH2 500/4885ACHE 1393/4885KMT2A 2517/4885 |
| US-20120065237-A1 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES | TTR, TTPA, PRNP | KCNH2 4277/4885ACHE 1685/4885KMT2A 4571/4885 |
| US-20120135981-A1 | NOVEL SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, APH1A | KCNH2 3998/4885ACHE 235/4885KMT2A 2877/4885 |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | KCNH2 64/4885ACHE 4738/4885KMT2A 3837/4885 |
| US-20100120919-A1 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES | TTR, TTPA, PRNP | KCNH2 4277/4885ACHE 1685/4885KMT2A 4571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.